Pseudomonas Aeruginosa Infection Clinical Trial
Official title:
Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals
Isolation and identification of Pseudomonas aeruginosa using basic microbiological methods, such as Gram staining, cultivation on cetrimide agar and biochemical reactions from Samples from patients with different types of health care associated infections as urinary tract infections, infected burn, ventilator associated pneumonia, blood stream infections and surgical site infections that will be obtained under complete aseptic precautions.
| Status | Recruiting |
| Enrollment | 100 |
| Est. completion date | March 1, 2025 |
| Est. primary completion date | November 1, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year to 80 Years |
| Eligibility | Inclusion Criteria: - Samples from patients with different types of health care associated infections as urinary tract infections, infected burn, ventilator associated pneumonia, blood stream infections and surgical site infections will be obtained under complete aseptic precautions. Exclusion Criteria: - Any infection before 48 hours of patient admission at Hospital |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Faculty of medicine Sohag university hospital | Sohag |
| Lead Sponsor | Collaborator |
|---|---|
| Sohag University |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Isolation and identification of pseudomonas aeruginosa causing different nosocomial infections. | Isolation and identification of Pseudomonas aeruginosa using basic microbiological methods, such as Gram staining, cultivation on cetrimide agar and biochemical reactions | 6 months | |
| Primary | Identification of antibiotic susceptibility pattern of isolated strains of pseudomonas | Antibiotic susceptibility testing of the isolates will be performed using disc diffusion method according to clinical laboratory standards institute (CLSI) guidelines | 6 months | |
| Primary | Detection of biofilm forming isolates | Detection of biofilm forming isolates by tissue culture plate method. | 6 months | |
| Primary | Detection of virulence and antibiotic resistance genes of pseudomonas aeruginosa. | Detection of virulence and antibiotic resistance genes by conventional Polymerase Chain Reaction | 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06093191 -
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
|
Phase 4 | |
| Completed |
NCT02421120 -
Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
|
Phase 4 | |
| Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 | |
| Completed |
NCT01577368 -
Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa
|
Phase 3 | |
| Completed |
NCT04803708 -
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01563263 -
Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43
|
Phase 2/Phase 3 | |
| Completed |
NCT01315678 -
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
|
Phase 3 | |
| Completed |
NCT01429259 -
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
|
Phase 4 | |
| No longer available |
NCT04636554 -
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
|